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Abstract
Breakpoint cluster region‐Abelson murine leukemia (BCR‐ABL) inhibitors mark-
edly improve the prognosis of chronic myeloid leukemia. However, high treatment 
adherence is necessary for successful treatment with BCR‐ABL inhibitors. Therefore, 
an adequate understanding of the adverse event profiles of BCR‐ABL inhibitors is 
essential. Although many adverse events are observed in trials, an accurate identifi-
cation of adverse events based only on clinical trial results is difficult because of 
strict entry criteria or limited follow‐up durations. In particular, BCR‐ABL inhibi-
tor‐induced impaired glucose metabolism remains controversial. Pharmacovigilance 
evaluations using spontaneous reporting systems are useful for analyzing drug‐re-
lated adverse events in clinical settings. Therefore, we conducted signal detection 
analyses for BCR‐ABL inhibitor‐induced impaired glucose metabolism by using the 
FDA Adverse Event Reporting System (FAERS) and Japanese Adverse Drug Event 
Report (JADER) database. Signals for an increased reporting rate of impaired glu-
cose metabolism were detected only for nilotinib use, whereas these signals were not 
detected for other BCR‐ABL inhibitors. Subgroup analyses showed a clearly in-
creased nilotinib‐associated reporting rate of impaired glucose metabolism in male 
and younger patients. Although FAERS‐ and JADER‐based signal detection analy-
ses cannot determine causality perfectly, our study suggests the effects on glucose 
metabolism are different between BCR‐ABL inhibitors and provides useful informa-
tion for the selection of appropriate BCR‐ABL inhibitors.
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1 |  INTRODUCTION
Chronic myeloid leukemia (CML) is a clonal stem cell neo-
plasm characterized by the presence of the Philadelphia (Ph) 
chromosome.1 The Ph chromosome produces the break-
point cluster region‐Abelson murine leukemia (BCR‐ABL) 
fusion protein, which dysregulates tyrosine kinase activity 
and induces uncontrolled proliferation of the granulocyte 
lineage. Imatinib, nilotinib, dasatinib, bosutinib, and pona-
tinib are tyrosine kinase inhibitors that inhibit the activity 
of the BCR‐ABL fusion protein. These BCR‐ABL inhibi-
tors have been reported to improve markedly the prognosis 
of CML.2-6 However, maintaining high therapeutic adher-
ence is necessary to obtain the maximum therapeutic effect 
with BCR‐ABL inhibitors.7 For instance, an adequate blood 
concentration of imatinib is necessary to obtain the maxi-
mum therapeutic effect.8 However, adverse events induced 
by BCR‐ABL inhibitors decrease therapeutic adherence. 
Therefore, a good understanding of the adverse event pro-
file of BCR‐ABL inhibitors is essential for successful CML 
treatment.
Adverse events related to a class effect or a drug effect 
of BCR‐ABL inhibitors have been observed in clinical trials. 
Cardiovascular toxicity was reported as a common adverse 
event induced by all BCR‐ABL inhibitors,9 while impaired 
glucose metabolism was reported in cases of nilotinib use.10-12 
Impaired glucose metabolism increases the risk of cardiovas-
cular events and limits the patients who can receive nilotinib 
treatment. Furthermore, these adverse events decrease patient 
adherence to BCR‐ABL inhibitors. However, there have been 
no reports related to impaired glucose metabolism caused by 
imatinib or dasatinib. Imatinib, in fact, has been reported to 
facilitate the recovery of glucose metabolism.13-15 However, 
because these findings were reported in case reports or stud-
ies with low reliability, the effects of BCR‐ABL inhibitors 
on glucose metabolism remain controversial, and there is no 
choice but to treat this adverse event empirically. Therefore, 
it is important to understand this adverse event induced by 
BCR‐ABL inhibitors to promote their proper use. Several 
studies have indicated that the safety data provided by clinical 
trials do not reflect data from real clinical settings because 
of strict entry criteria or limited follow‐up durations.9 The 
long‐term follow‐up data, including the data of patients with 
various comorbidities in real clinical settings, are essential 
for understanding the accurate impact of BCR‐ABL inhib-
itors on glucose metabolism. However, these analyses were 
rarely conducted and the detailed characteristics of this ad-
verse event remain unclear.
In recent years, spontaneous reporting systems (SRS) re-
flecting data from actual clinical practice have been used to 
evaluate drug safety. The US Food and Drug Administration 
(FDA) manages the FDA Adverse Event Reporting System 
(FAERS), which has registered more than three million 
spontaneous reports of adverse events and is the largest SRS 
database in the world.16 In Japan, the Pharmaceuticals and 
Medical Devices Agency (PMDA) manages the Japanese 
Adverse Drug Event Report (JADER) database, which has 
registered approximately 300 000 spontaneous reports of ad-
verse events.17 These databases are publically available and 
reflect full adverse event profiles in real clinical settings. 
Therefore, these databases are used in pharmacovigilance 
analyses and are useful for evaluating the risk of adverse 
events reflected in real clinical settings.18-21
The aim of this study was to analyze the relationship 
between BCR‐ABL inhibitors and impaired glucose me-
tabolism using FAERS and the JADER database. We also 
evaluated the characteristics of impaired glucose metabolism 
induced by BCR‐ABL inhibitors.
2 |  MATERIAL AND METHODS
2.1 | Database source
Adverse event reports were downloaded from the FDA and 
PMDA websites.22,23 JADER data until May 2017, which 
are publicly available on the PMDA website, were used. 
For FAERS analysis, data from the third quarter of 2010 
to the second quarter of 2015 were used. Because FAERS 
includes duplicate reports, only the latest report of a patient 
was used for analysis according to the recommendation of 
the FDA.24 Only reports with complete age and sex infor-
mation were extracted. Furthermore, we analyzed reports 
with patient ages greater than 20 years in this analysis. 
Supplemental analysis using all reports was also per-
formed. Reporting odds ratios (RORs) were used for eval-
uating signal detection. Each case was divided into four 
groups based on whether “Impaired glucose metabolism” 
developed and whether a BCR‐ABL inhibitor was used. 
Namely, there were (n11) cases who used a BCR‐ABL 
inhibitor and reported as “Impaired glucose metabolism,” 
(n12) cases who used a BCR‐ABL inhibitor and did not 
report as “Impaired glucose metabolism,” (n21) cases who 
did not use a BCR‐ABL inhibitor and reported as “Impaired 
glucose metabolism,” and (n22) cases who did not use a 
BCR‐ABL inhibitor and did not report as “Impaired glu-
cose metabolism.” The ROR and 95% confidence interval 
(CI) were calculated by the following formula.24
A signal was considered detected when the lower limit 
of the 95% CI of the ROR exceeded one. In the subgroup 
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subgroups because age was described in 10‐year incre-
ments. Additionally, time‐onset analysis was performed 
using the drug administration start date and the adverse 
event occurrence date included in the JADER database. 
The downloaded data were processed using Microsoft 
Access 2016® (Microsoft, Redmond, WA). All data 
analyses were performed in more than two independent 
experiments.
2.2 | Outcomes
In JADER and FAERS, the descriptions of adverse event 
names conform to the Medical Dictionary for Regulatory 
Activities (MedDRA) developed by the International 
Conference on Harmonisation of Technical Requirements 
for Registration of Pharmaceuticals for Human Use (ICH). 
Therefore, the adverse events that were defined using 
MedDRA conformed to the adverse event names in our 
study. Impaired glucose metabolism is defined by 113 pre-
ferred terms that were included in the standardized MedDRA 
queries “hyperglycemia/new onset diabetes mellitus” (SMQ 
20000041).
2.3 | Statistical analysis
Categorical variables are summarized in terms of frequen-
cies and percentages. The Fisher exact test was used to 
compare the frequency of adverse events in the presence or 
absence of BCR‐ABL inhibitors. Days from the administra-
tion of nilotinib to the onset of impaired glucose metabo-
lism in nilotinib‐administered patients were analyzed by the 
Kaplan‐Meier method. The analyses were performed using R 
statistical software version 3.3.2. Statistical significance was 
defined as a P‐value <0.05.
3 |  RESULTS
3.1 | Reporting rate of impaired glucose 
metabolism reported in FAERS and the 
JADER database
In FAERS, 572, 306, 514, 42, and 114 cases of impaired 
glucose metabolism associated with imatinib, dasatinib, nilo-
tinib, bosutinib, and ponatinib, respectively, were reported 
(Table 1). In the JADER database, 75, 23, 93, and three cases 
of impaired glucose metabolism associated with imatinib, da-
satinib, nilotinib, and bosutinib, respectively, were reported. 
No cases associated with ponatinib were reported in the 
JADER database. The ROR of impaired glucose metabolism 
associated with nilotinib was 1.26 (95% CI: 1.149‐1.382) in 
FAERS and 1.32 (95% CI: 1.059‐1.634) in the JADER data-
base, and signals for an increased reporting rate of impaired 
glucose metabolism were detected (P < 0.001). In contrast, 
the RORs of impaired glucose metabolism associated with 
imatinib and dasatinib were 0.79 (95% CI: 0.722‐0.857) and 
0.80 (95% CI: 0.708‐0.896), respectively, in FAERS and 0.40 
(95% CI: 0.313‐0.503) and 0.41 (95% CI: 0.261‐0.625), re-
spectively, in the JADER database; signals for an increased 
reporting rate of impaired glucose metabolism were not de-
tected. These signals were also not detected for bosutinib 
(ROR: 0.64, 95% CI: 0.459‐0.876) and ponatinib (ROR: 
1.10, 95% CI: 0.900‐1.335) in the FAERS database.
3.2 | Relationship between impaired glucose 
metabolism and sex
In FAERS, signals for an increased reporting rate of impaired 
glucose metabolism were detected for nilotinib regardless of 
sex (male: ROR, 1.23, 95% CI, 1.088‐1.394; female: ROR, 
1.28, 95% CI, 1.107‐1.466) (Table 2). In the JADER database, 
T A B L E  1  Incidences of impaired glucose metabolism induced by BCR‐ABL inhibitors reported in FAERS and the JADER database
Drug A
Impaired glucose metabolism 
without Drug A
Impaired glucose metabolism with 
Drug A ROR 95% CI P value
FAERS
Imatinib 176 388/2 167 224 (8.86%) 572/8771 (6.52%) 0.79 0.722‐0.857 <0.001
Dasatinib 176 654/2 171 358 (8.86%) 306/4637 (6.6%) 0.80 0.708‐0.896 <0.001
Nilotinib 176 446/2 170 873 (8.85%) 514/5122 (10.04%) 1.26 1.149‐1.382 <0.001
Bosutinib 176 918/2 175 214 (8.85%) 42/781 (5.38%) 0.64 0.459‐0.876 0.004
Ponatinib 176 846/2 174 711 (8.85%) 114/1284 (8.88%) 1.1 0.9‐1.335 0.332
JADER
Imatinib 20 064/378 563 (5.6%) 75/3429 (2.19%) 0.40 0.313‐0.503 <0.001
Dasatinib 20 116/380 973 (5.57%) 23/1019 (2.26%) 0.41 0.261‐0.625 <0.001
Nilotinib 20 046/380 634 (5.56%) 93/1358 (6.85%) 1.32 1.059‐1.634 0.012
Bosutinib 20 136/381 868 (5.57%) 3/124 (2.42%) 0.45 0.091‐1.333 0.223
CI, confidence interval; FAERS, Food and Drug Administration Adverse Event Reporting System; JADER, Japanese Adverse Drug Event Report; ROR, reporting odds 
ratio.
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signals for an increased reporting rate of impaired glucose 
metabolism were detected in only the male groups treated 
with nilotinib (male: ROR, 1.37, 95% CI, 1.034‐1.783; fe-
male: ROR, 1.23, 95% CI, 0.839‐1.757). These signals were 
not detected for other BCR‐ABL inhibitors regardless of sex.
3.3 | Relationship between impaired glucose 
metabolism and age
In FAERS, signals for an increased reporting rate of impaired 
glucose metabolism were detected for nilotinib regardless 
of age (20‐60 s: ROR, 1.16, 95% CI, 1.031‐1.299; 70‐90 s: 
ROR, 1.47, 95% CI, 1.257‐1.714) (Table 3). In the JADER 
database, signals for an increased reporting rate of impaired 
glucose metabolism were detected in only the younger 
group treated with nilotinib (20‐60 s: ROR, 1.51, 95% CI, 
1.127‐1.991; 70‐90 s: ROR, 1.11, 95% CI, 0.779‐1.550). 
These signals were not detected for other BCR‐ABL inhibi-
tors regardless of age.
3.4 | Time‐onset analysis of impaired 
glucose metabolism using the JADER database
The time‐onset analysis showed that the reports of impaired 
glucose metabolism induced by nilotinib increased within 
200 days. However, late‐onset events beyond 600 days were 
also reported (Figure 1).
4 |  DISCUSSION
Our analyses using FAERS and the JADER database revealed 
that signals for an increased reporting rate were detected only 
for nilotinib. These signals were clearly detected in male or 
younger patients. However, these signals were not detected 
for other BCR‐ABL inhibitors.
Our study showed the relationship between nilotinib 
and the increased reporting rate of impaired glucose me-
tabolism. However, the mechanism of impaired glucose 
T A B L E  2  Effect of sex on impaired glucose metabolism reported in FAERS and the JADER database
Drug A
Impaired glucose metabolism 
without Drug A
Impaired glucose metabolism 
with Drug A ROR 95% CI P value
FAERS
Male
Imatinib 67 905/815 539 (9.08%) 266/4850 (5.48%) 0.64 0.562‐0.723 <0.001
Dasatinib 68 023/818 027 (9.07%) 148/2362 (6.27%) 0.74 0.62‐0.871 <0.001
Nilotinib 67 882/817 513 (9.06%) 289/2876 (10.05%) 1.23 1.088‐1.394 0.001
Bosutinib 68 151/820 016 (9.06%) 20/373 (5.36%) 0.63 0.377‐0.98 0.039
Ponatinib 68 115/819 727 (9.06%) 56/662 (8.46%) 1.02 0.761‐1.342 0.888
Female
Imatinib 108 483/1 351 685 (8.73%) 306/3921 (7.8%) 0.97 0.86‐1.091 0.638
Dasatinib 108 631/1 353 331 (8.73%) 158/2275 (6.95%) 0.86 0.723‐1.006 0.058
Nilotinib 108 564/1 353 360 (8.72%) 225/2246 (10.02%) 1.28 1.107‐1.466 <0.001
Bosutinib 108 767/1 355 198 (8.73%) 22/408 (5.39%) 0.65 0.405‐1.003 0.055
Ponatinib 108 731/1 354 984 (8.72%) 58/622 (9.32%) 1.18 0.883‐1.546 0.237
JADER
Male
Imatinib 10 395/192 651 (5.7%) 35/1926 (1.82%) 0.32 0.225‐0.453 <0.001
Dasatinib 10 418/194 001 (5.67%) 12/576 (2.08%) 0.37 0.193‐0.66 <0.001
Nilotinib 10 370/193 742 (5.66%) 60/835 (7.19%) 1.37 1.034‐1.783 0.025
Bosutinib 10 427/194 499 (5.66%) 3/78 (3.85%) 0.71 0.142‐2.145 0.800
Female
Imatinib 9669/185 912 (5.49%) 40/1503 (2.66%) 0.5 0.354‐0.682 <0.001
Dasatinib 9698/186 972 (5.47%) 11/443 (2.48%) 0.47 0.231‐0.842 0.007
Nilotinib 9676/186 892 (5.46%) 33/523 (6.31%) 1.23 0.839‐1.757 0.235
Bosutinib 7162/157 401 (4.77%) 0/41 (0%) ‐ ‐ ‐
CI, confidence interval; FAERS, Food and Drug Administration Adverse Event Reporting System; JADER, Japanese Adverse Drug Event Report; ROR, reporting odds 
ratio.
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metabolism induced by nilotinib remains unclear. Some 
case reports have suggested that nilotinib decreases insulin 
sensitivity or inhibits insulin secretion, causing impaired 
glucose metabolism.25,26 However, because only a few 
studies have referred to this phenomenon, the increase in 
the risk of impaired glucose metabolism induced by nilo-
tinib was evaluated empirically herein. Signals of increased 
reporting rate were detected for nilotinib in the analysis 
comprising all patient reports in FAERS, and this trend 
was also observed in the analysis based on the JADER da-
tabase (Table S1). Therefore, this result is considered valid. 
Follow‐up analysis for 5 years in the patients who received 
nilotinib or imatinib revealed that increased glucose levels 
were clearly observed in nilotinib‐treated patients, which is 
consistent with our results.27 To our knowledge, this study 
is the first to demonstrate the relationship between nilo-
tinib and increased risk of impaired glucose metabolism. 
A reduction in the risk of cardiovascular events is neces-
sary to maintain the quality of life during CML treatment.28 
Our study suggests avoiding nilotinib treatment for patients 
with diabetes or other diseases that increase the risk of car-
diovascular events. The time‐onset analysis revealed that 
impaired glucose metabolism induced by nilotinib was re-
ported at more than a year. This result highlights the im-
portance of continuous monitoring of blood glucose levels 
during nilotinib treatment. The subgroup analyses revealed 
that the signals of increased reporting rate of impaired glu-
cose metabolism induced by nilotinib were clearly detected 
in male or younger patients. BCR‐ABL inhibitor treatment 
lasts a lifetime. Therefore, it may be better to avoid nilo-
tinib treatment in younger patients with a high risk of dia-
betes mellitus.
Decreased adherence to BCR‐ABL inhibitor treatment 
commonly occurs.29 Although age and sex were reported as 
the factors for limiting adherence, adverse events induced by 
BCR‐ABL inhibitors also decrease adherence.30 Early detec-
tion of adverse events and adequate supportive care is use-
ful to improve adherence. Moreover, Leader et al31 reported 
T A B L E  3  Effect of age on impaired glucose metabolism reported in FAERS and the JADER database
Drug A
Impaired glucose metabolism 
without Drug A
Impaired glucose metabolism 
with Drug A ROR 95% CI P value
FAERS
20‐60 s
Imatinib 132 131/1 641 998 (8.75%) 393/6392 (6.15%) 0.75 0.674‐0.829 <0.001
Dasatinib 132 304/1 645 007 (8.75%) 220/3383 (6.5%) 0.8 0.69‐0.912 <0.001
Nilotinib 132 199/1 644 856 (8.74%) 325/3534 (9.2%) 1.16 1.031‐1.299 0.013
Bosutinib 132 497/1 647 848 (8.74%) 27/542 (4.98%) 0.6 0.391‐0.883 0.007
Ponatinib 132 444/1 647 417 (8.74%) 80/973 (8.22%) 1.02 0.805‐1.289 0.814
70‐90 s
Imatinib 44 257/525 227 (9.2%) 179/2379 (7.52%) 0.88 0.755‐1.031 0.120
Dasatinib 44 350/526 352 (9.2%) 86/1254 (6.86%) 0.8 0.635‐0.997 0.047
Nilotinib 44 247/526 018 (9.18%) 189/1588 (11.9%) 1.47 1.257‐1.714 <0.001
Bosutinib 44 421/527 367 (9.2%) 15/239 (6.28%) 0.73 0.401‐1.227 0.293
Ponatinib 44 402/527 295 (9.19%) 34/311 (10.93%) 1.33 0.906‐1.911 0.124
JADER
20‐60 s
Imatinib 10 542/223 081 (4.96%) 40/2088 (1.92%) 0.39 0.28‐0.538 <0.001
Dasatinib 10 565/224 491 (4.94%) 17/678 (2.51%) 0.52 0.301‐0.841 0.005
Nilotinib 10 527/224 375 (4.92%) 55/794 (6.93%) 1.51 1.127‐1.991 0.005
Bosutinib 10 581/225 096 (4.93%) 1/73 (1.37%) 0.28 0.007‐1.62 0.265
70‐90 s
Imatinib 9522/155 482 (6.52%) 35/1341 (2.61%) 0.41 0.285‐0.575 <0.001
Dasatinib 9551/156 482 (6.5%) 6/341 (1.76%) 0.28 0.1‐0.606 <0.001
Nilotinib 9519/156 259 (6.49%) 38/564 (6.74%) 1.11 0.779‐1.55 0.536
Bosutinib 9555/156 772 (6.49%) 2/51 (3.92%) 0.63 0.074‐2.397 0.770
CI, confidence interval; FAERS, Food and Drug Administration Adverse Event Reporting System; JADER, Japanese Adverse Drug Event Report; ROR, reporting odds 
ratio.
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that multidisciplinary intervention improved the adherence 
to BCR‐ABL inhibitors. Our studies provide useful informa-
tion for conducting optimal supportive care to improve this 
adherence.
There are some limitations associated with FAERS and 
the JADER database because these databases are reporting 
systems for spontaneous adverse events. Data from these da-
tabases were collected from various clinical settings wherein 
adverse event reporting was voluntary. Therefore, these data-
bases might include duplicate data.32 We excluded duplicate 
data according to the recommendation of the FDA. In addi-
tion to the possibility of an over‐reporting bias, an under‐re-
porting bias, due to nonreporting of adverse events by health 
care workers, exists.32 It is known that spontaneous adverse 
event reports tend to increase after drug safety alerts or pub-
lications, which is called notoriety bias.33 Considering these 
reporting biases, caution should be exercised when interpret-
ing results obtained from only one SRS database. In our study, 
we used two SRS databases, FAERS and the JADER data-
base, to overcome reporting biases and increase the reliability 
of our results. FAERS is one of the largest SRS databases in 
the world and is suitable for analyzing the risk detection of 
adverse events induced by medications, owing to the large 
number of reports. However, this database does not include 
detailed data pertaining to adverse events, such as durations 
of medication administration and patient characteristics. In 
contrast, the JADER database contains detailed patient char-
acteristics and adverse events, although the number of reports 
is lower than that in FAERS because the JADER database 
contains data from only Japanese patients. Our results have 
high reliability because the same results were obtained from 
two databases. Although we recognize the limitations associ-
ated with SRS, our study provides useful evidence showing 
differences in the effects on impaired glucose metabolism be-
tween BCR‐ABL inhibitors.
We used RORs to detect signals of risk increase or de-
crease. In data mining analyses, proportional reporting ratios 
(PRR) and multi‐item gamma Poisson Shrinker (MGPS) are 
used for signal detection algorithms.9,32 Although all algo-
rithms showed high specificity, each algorithm showed dif-
ferent sensitivity.34 The detection sensitivity of MGPS is 
26%, and we should consider overlooking risk when using 
MGPS‐based algorithms. On the contrary, ROR and PRR 
have high sensitivity. Especially, ROR is usually used in sig-
nal detection algorithms due to its simplicity.17,21,24 However, 
ROR‐based algorithms have the disadvantage of decreased 
detection power when the number of adverse event reports 
is small. The number of reports of impaired glucose metab-
olism related to BCR‐ABL inhibitors was not small, and it 
was reasonable to use ROR in signal detection in our study. A 
high ROR indicates an increase in the risk of an adverse event 
report, not an increase in the risk of development of adverse 
events. Therefore, we are aware that an increased ROR only 
offers a rough indication of signal strength.
Despite the inherent limitations of signal detection using 
SRS databases, our results regarding the differences in the ef-
fects on impaired glucose metabolism between BCR‐ABL in-
hibitors are in agreement with the results of previous studies. 
Thus, our study provides beneficial information for the man-
agement of adverse events induced by BCR‐ABL inhibitors.
5 |  CONCLUSION
Our study using FAERS and the JADER database revealed 
that the use of nilotinib increased the reporting rate of im-
paired glucose metabolism, whereas other BCR‐ABL in-
hibitors did not increase reports of this adverse event. This 
finding indicated that only nilotinib increased the risk of 
impaired glucose tolerance and that adverse events might be 
drug effects of nilotinib and not class effects of BCR‐ABL 
inhibitors. Although further analyses are required to confirm 
these findings, our results indicated differences in the effect 
on glucose metabolism between BCR‐ABL inhibitors and 
that careful monitoring of glucose levels is necessary among 
nilotinib‐treated patients.
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